Newport Beach-based Evolus Inc. (NASDAQ: EOLS), whose flagship neurotoxin product, Jeuveau, competes with Botox in the aesthetics industry, named Sandra Beaver as its chief financial officer, effective September 5.
Beaver was senior vice president of finance at Experian, where she was responsible for consolidated financial planning and analysis for half of the company’s North America B2B business units with revenue in excess of $1 billion.
“Sandra brings a fresh perspective, along with deep financial and operational experience in highly regulated industries that will help take Evolus to the next level,” Evolus Chief Executive David Moatazedi said in a statement.
Evolus in March announced the retirement of Lauren Silvernail, who had been CFO since 2018 and was 63 according to the latest proxy published in March. According to the proxy, Silvernail, who left in May, owned 383,000 shares that are currently worth almost $4 million.
Evolus shares rose 1.7% to $10.28 and a $574.4 million market cap.